glp 1 tirzepatide mounjaro Lilly's tops other GLP-1s for some type 2 diabetes patients FDA approves tirzepatide, Eli Lilly's

Erring on the side of caution is appropriate

Zepbound is Eli Lillys new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA in November 2023, showing great promise compared to the other GLP-1R agonists on the market

Skin looks younger since it has been raised and tightened

Standard injection protocol: Dose: 1 to 2 mg daily Duration: 10 to 20 day cycles Frequency: 1 to 3 cycles per year, spaced 4 to 6 months apart Timing: Evening administration to align with natural melatonin production timing Administration: Subcutaneous or intramuscular Maintenance protocol (sublingual): Daily sublingual sprays between injection cycles Lower bioavailability than injection but convenient for ongoing support The cyclic nature of Epitalon protocols reflects how the peptide works